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ABSTRACT
OBJECTIVES To assess the current training and 
further education available to prospective Responsible 
Persons (RPs), to gather feedback from current RPs and 
industry stakeholders’ experiences and to recommend 
guidelines on what training and experience prospective 
RPs should undergo to become eligible for the role. 
METHOD A focus group was organised with key 
stakeholders from the industry including representatives 
from the Medicines Authority, University of Malta and the 
Central Procurement and Supplies Unit (CPSU). Feedback 
on individual experiences was gathered.
KEY FINDINGS The most common recommendation 
from the focus group was the emphasis on the importance 
of having practical experience relative to the size and 
complexity of the operation.
CONCLUSION Guidelines to be proposed for a 
framework on accepting RPs should consider experience 
supported by knowledge on obligations and duties to be 
fulfilled by the RP.
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Introduction
Article 79(b) of EU Directive 2001/83/EC states that the 
holder of a wholesale dealer’s license in Europe is to have 
“a Qualified Person designated as responsible, meeting the 
conditions provided for by the legislation of the Member 
State concerned.”1 To comply with this directive the Maltese 
Law specifies that the Responsible Person (RP) has to be 
registered with the Pharmacy Council as a pharmacist and 
recognised as suitable by the Malta Medicines Authority 
(MA).2 The MA does not interview prospective candidates 
to assess their competence and knowledge prior to 
recognising their role as RP. It currently recognises any 
registered pharmacist that is listed on the wholesale dealers 
license application form. Principles of Good Distribution 
Practice (GDP) require that RPs have experience and 
knowledge in areas related to distribution of medicines 
such as risk management, change and deviation control.3
Method
Legislation regarding eligibility for RPs in Europe was 
identified. The search yielded minimal results. Guidelines 
and recommendations from concerned organisations 
were assessed and relevant findings recorded. Non-
European frameworks for countries where a mutual 
recognition agreement exists with the EU such as Canada 
and third countries were explored to gain an outside 
perspective on the subject. A focus group was carried 
out with stakeholders from the pharmaceutical industry. 
The group consisted of 6 participants representing 
pharmaceutical regulatory authorities, academia and the 
pharmaceutical industry. The questions asked aimed to 
gather current perception of the different stakeholders on 
the role of the RP, procedure for becoming a RP and the 
need for a RP. Challenges that RPs face and recommended 
training for RPs were also discussed. 
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Results
There was agreement between the focus group participants 
that the RP is mandated to release medicines for distribution 
by ensuring that they have been stored and distributed in 
accordance with GDP guidelines. It was agreed that this can 
be done through establishment of an effective quality system 
that is relevant to the complexity of the distribution activity. 
RPs must be practical, knowledgeable and able to adapt to 
the exigencies of the company whilst being aware of their 
corporate social responsibility without compromising on 
product quality or integrity.
In the first question, the participants were asked to state 
what they understood by the term ‘Responsible Person’. The 
current RPs described their current function as: “Releasing 
medicine for use, carrying out the registration process 
and monitoring, taking care of legal aspects involved 
and documentation keeping”. Participants with less 
technical backgrounds focused on quality of medicines: 
“The person who is the gateway for medicinal products 
to be released on the markets following purchase from 
a manufacturer and wholesale dealer supplier ensuring 
that GDP guidelines are adhered to, safeguarding the 
integrity of the medicines”. The representatives from the 
Medicines Authority made reference to the national and EU 
legal framework: “The Responsible Person is the person 
mandated by law to ascertain what the activities of a 
wholesaler are in line with the legal requirements and EU 
GDP guidelines. On a practical level the RP is the person 
to see that the products passing from the suppliers to the 
clients are safe and their quality has been maintained”. 
There is a general consensus that the industry understands 
that the function of a RP is to release medicines for distribution 
and safeguarding quality of medicines throughout the 
supply chain through compliance with GDP guidelines. The 
group highlighted the legal responsibility of the RP and the 
authority this brings about in decisions regarding acceptance 
or rejection of goods.
The second question of the focus group asked the participants 
to describe the role of the RP. The answers were similar for 
all participants since they were aware of the role of the RP 
and where jurisdiction started and ended. It was understood 
that the RP is the key player in the supply chain and that 
the role takes over from the Qualified Person in the chain of 
responsibility. The role of an RP is to ensure compliance with 
GDP guidelines through use of an effective quality system. 
The third question of the focus group aimed to disclose 
challenges faced by RPs from aspects of the industry. 
Different feedback was given from each stakeholder. The 
established RP felt that the constant struggle between 
the lack of appreciation of the role of the RP and financial 
costs involved with compliance was the biggest challenge. 
A participant who was a newly appointed RP felt that the 
major challenge faced was the lack of resources available to 
provide support in improving knowledge. The stakeholder 
from the industry stated that the biggest challenge was the 
struggle faced trying to obtain and deliver the medicine 
quickly to the patient despite delays due to regulatory 
procedures. Another challenge faced was the costs with 
respect to GDP compliance. The regulator’s perspective was 
more balanced as both sides of the story were laid out. There 
were compliance and financial pressures involving the RP 
and license holder. 
The final question aimed to identify the expectations of the 
industry regarding the experience and background of the RP 
and their opinion in reaching the desired level of knowledge 
and experience. There was agreement that experience was 
the most important asset required by a RP. This experience 
had to be relevant to the complexity of the activity involved. 
Knowledge on basic and advanced concepts was deemed 
important but secondary to experience.
There was agreement that experience was the  
most important asset required by a RP... This experience had  
to be relevant to the complexity of the activity involved
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Discussion
Maltese Legislation dictates that the RP must be a pharmacist 
and must be deemed suitable by the Medicines Authority.2 
The RP who is nominated by the License Holder, must 
ensure that wholesale dealing activities are carried out in 
line with EU Guidelines of GDP. A company may have more 
than one RP who is nominated for the same license, in such 
cases all RPs would be equally responsible for the activities 
carried out by the company. The rationale behind the law 
choosing pharmacists as the sole eligible candidates for 
the role of RPs was that the pharmacy course adequately 
prepared pharmacists for the role. As regulations increased 
in complexity, there is a need for course updating. To tackle 
this problem, new credits and modules may be considered 
within the course and as refresher courses. Moreover 
from this study it transpired that the focus needs to be on 
experience.  
Conclusion
Although having improperly trained or inexperienced RPs 
is a local problem, the consequences of an error committed 
by these individuals may have ramifications all over the 
European Community. The European Union relies heavily on 
its member states’ controls to ensure that a single European 
market can be maintained in a safe and absolute manner. 
As the saying goes, “Experience is the best teacher” (Anon) 
and having experienced RPs is one way of mitigating the 
problems stated above. RPs are part of a team of individuals 
and are responsible for compliance. They have obligations 
to their employers and patients. This study has highlighted 
the importance of including experience within guidelines 
for criteria necessary to become an RP. More awareness is 
needed about the importance of the RP’s role as prospective 
RPs need to be fully aware of the responsibility they are 
taking on, as well as the consequences of their actions. The 
industry needs to appreciate and support the RP in their 
work as without support the RP cannot function.
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